Prokinetic agents – their contribution to practice of gastroenterology

Czech version

Authors: A. Hep ¹; J. Dolina ²
Authors‘ workplace: Interní gastroenterologická klinika Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Aleš Hep, CSc. ¹; Endoskopické centrum FN Brno, pracoviště Bohunice, přednosta prim. MUDr. Jiří Dolina, Ph. D. ²
Published in: Vnitř Lék 2011; 57(9): 693-696
Category: 65th birthday Mudr. Jany Laciné and and 60th birthday Milana Tržila

Overview

Motility plays a fundamental role in the functioning of the gastrointestinal tract. Prokinetic agents are thus an important treatment modality in patients with functional and certain organ diseases with underlying functional modifications. Gastro-oesophageal reflux disease is frequently associated with a disorder of oesophageal motility, an alteration of gastric evacuation may manifest as an atypical dyspeptic complaint. Prokinetic agents may also be effective in other disease states, such as diabetic gastroparesis, malignant conditions associated with nausea and vomiting, motility disorders in preterm babies etc.

Key words:
functional disorders – prokinetic agents – gastro-oesophageal reflux disease – irritable bowel syndrome – dyspeptic syndrome – motility

Sources

1. Bruley des Varannes S, Coron E, Galmiche JP. Short and long-term PPI treatment for GERD. Do we need more-potent anti-secretory drugs? Best Pract Res Clin Gastroenterol 2010; 24: 905–921.

2. van Pinxteren B, Sigterman KE, Bonis P et al. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 2010; 11: CD002095.

3. Tosetti C, Bellentani S, Benedetto E et al. The management of patients with new onset of upper gastro-intestinal symptoms in primary care. Dig Liver Dis 2010; 42: 860–864.

4. Tighe MP, Afzal NA, Bevan A et al. Current pharmacological management of gastro-esophageal reflux in children: an evidence-based systematic review. Paediatr Drugs 2009; 11: 185–202.

5. Koshino K, Adachi K, Furuta K et al. Effects of mosapride on esophageal functions and gastroesophageal reflux. J Gastroenterol Hepatol 2010; 25: 1066–1071.

6. Bredenoord AJ. New therapies for gastroesophageal reflux disease. Minerva Gastroenterol Dietol 2010; 56: 129–138.

7. Ponce J, Mearin F, Ponce M et al. Symptom profile in gastroesophageal reflux disease in untreated patients and those with persistent symptoms despite treatment. Gastroenterol Hepatol 2010; 33: 271–279.

8. Donnellan C, Preston C, Moayyedi P et al. WITHDRAWN: Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev 2010; 2: CD003245.

9. Miwa H, Inoue K, Ashida K et al. Japan TREND study group. Randomised clinical trial: efficacy of the addition of a prokinetic, mosapride citrate, to omeprazole in the treatment of patients with non-erosive reflux disease – a double-blind, placebo-controlled study. Aliment Pharmacol Ther 2011; 33: 323–332.

10. Futagami S, Iwakiri K, Shindo T et al. The prokinetic effect of mosapride citrate combined with omeprazole therapy improves clinical symptoms and gastric emptying in PPI-resistant NERD patients with delayed gastric emptying. J Gastroenterol 2010; 45: 413–421.

11. Hammer HF. Reflux-associated laryngitis and laryngopharyngeal reflux: a gastroenterologist’s point of view. Dig Dis 2009; 27: 14–17.

12. Mirbagheri SA, Sadeghi A, Amouie M et al. Pyloric injection of botulinum toxin for the treatment of refractory GERD accompanied with gastroparesis: a preliminary report. Dig Dis Sci 2008; 53: 2621–2626.

13. Ciovica R, Riedl O, Neumayer C et al. The use of medication after laparoscopic antireflux surgery. Surg Endosc 2009; 23: 1938–1946.

14. Kandulski A, Venerito M, Malfertheiner P. Therapeutic strategies for the treatment of dyspepsia. Expert Opin Pharmacother 2010; 11: 2517–2525.

15. Brun R, Kuo B. Functional dyspepsia. Therap Adv Gastroenterol 2010; 3: 145–164.

16. Miwa H, Watari J, Fukui H et al. Pathogenesis and management of functional dyspepsia. Nippon Rinsho 2010; 68: 1391–1401.

17. Miyamoto M, Manabe N, Haruma K. Efficacy of the addition of prokinetics for proton pump inhibitor (PPI) resistant non-erosive reflux disease (NERD) patients: significance of frequency scale for the symptom of GERD (FSSG) on decision of treatment strategy. Intern Med 2010; 49: 1469–1476.

18. Holtmann G, Gapasin J. Failed therapy and directions for the future in dyspepsia. Dig Dis 2008; 26: 218–224.

19. Gasbarrini G, Merra G, Candelli M et al. Evaluation of gastric emptying and gastrointestinal symptoms in dyspeptic patients before and after hydropinic therapy. Recenti Prog Med 2010; 101: 389–392.

20. Tack J, Blondeau K, Boecxstaens V et al. Review article: the pathophysiology, differential diagnosis and management of rumination syndrome. Aliment Pharmacol Ther 2011; 33: 782–788.

21. Al Samaraee A, McCallum IJ, Coyne PE et al. Nutritional strategies in severe acute pancreatitis: a systematic review of the evidence. Surgeon 2010; 8: 105–110.

22. Grundmann O, Yoon SL. Irritable bowel syndrome: epidemiology, diagnosis and treatment: an update for health-care practitioners. J Gastroenterol Hepatol 2010; 25: 691–699.

23. Barkun AN, Bardou M, Martel M et al. Prokinetics in acute upper GI bleeding: a meta-analysis. Gastrointest Endosc 2010; 72: 1138–1145.

24. Ducrotté P. Abdominal bloating: an up-to-date. Gastroenterol Clin Biol 2009; 33 (10–11 Suppl): F94–F100.

25. Bielefeldt K, Raza N, Zickmund SL. Different faces of gastroparesis. World J Gastroenterol 2009; 15: 6052–6060.

26. Keller GA, Ponte ML, Di Girolamo G. Other drugs acting on nervous system associated with QT-interval prolongation. Curr Drug Saf 2010; 5: 105–111.

27. Ionescu D, Iancu C, Ion D et al. Implementing fast-track protocol for colorectal surgery: a prospective randomized clinical trial. World J Surg 2009; 33: 2433–2438.

28. Cresi F, Marinaccio C, Russo MC et al. Short-term effect of domperidone on gastroesophageal reflux in newborns assessed by combined intraluminal impedance and pH monitoring. J Perinatol 2008; 28: 766–770.

29. Kashyap P, Farrugia G. Diabetic gastroparesis: what we have learned and had to unlearn in the past 5 years. Gut 2010; 59: 1716–1726.

30. Reddymasu SC, McCallum RW. Small intestinal bacterial overgrowth in gastroparesis: are there any predictors? J Clin Gastroenterol 2010; 44: e8–e13.

31. Gupta A, Dhiman RK, Kumari S et al. Role of small intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhotic patients with minimal hepatic encephalopathy. J Hepatol 2010; 53: 849–855.

32. Shaikh N, Kettern MA, Hanssens Y et al. A rare and unsuspected complication of Clostridium difficile infection. Intensive Care Med 2008; 34: 963–966.

33. Reddymasu SC, Lin Z, Sarosiek I et al. Efficacy of gastric electrical stimulation in improving functional vomiting in patients with normal gastric emptying. Dig Dis Sci 2010; 55: 983–987.

34. Lanuti M, Dedelva P, Morse CR et al. Management of Delayed Gastric Emptying After Esophagectomy With Endoscopic Balloon Dilatation of the Pylorus. Ann Thorac Surg 2011; 91: 1019–1024.

35. Bishop S, Young H, Goldsmith D et al. Bowel motions in critically ill patients: a pilot observational study. Crit Care Resusc 2010; 12: 182–185.

36. Lam HS, Ng PC. Use of prokinetics in the preterm infant. Curr Opin Pediatr 2011; 23: 156–160.

37. Fujii T, Nakabayashi T, Hashimoto S et al. Successful perioperative management of patients with Parkinson’s disease following gastrointestinal surgery: report of three cases. Surg Today 2009; 39: 807–810.

38. Keeley PW. Nausea and vomiting in people with cancer and other chronic diseases. Clin Evid (Online) 2009; pii: 2406.

39. Min BH, Son HJ, Kim JJ et al. Idiopathic proximal hemimegacolon: radiologic findings and analyses of clinical and physiological characteristics. Abdom Imaging 2010; 35: 291–295.

40. Di Saverio S, Catena F, Ansaloni L et al. Water-soluble contrast medium (gastrografin) value in adhesive small intestine obstruction (ASIO): a prospective, randomized, controlled, clinical trial. World J Surg 2008; 32: 2293–2304.

41. Almeida N, Figueiredo P, Freire P et al. The effect of metoclopramide in capsule enteroscopy. Dig Dis Sci 2010; 55: 153–157.

42. Chourasia D, Misra A, Pandey R et al. Gastric atrophy and intestinal metaplasia in a patient on long-term proton pump inhibitor therapy. Trop Gastroenterol 2008; 29: 172–174.

43. Postgate A, Tekkis P, Patterson N et al. Are bowel purgatives and prokinetics useful for small-bowel capsule endoscopy? A prospective randomized controlled study. Gastrointest Endosc 2009; 69: 1120–1128.

44. Tack J. Prokinetics and fundic relaxants in upper functional GI disorders. Curr Opin Pharmacol 2008; 8: 690–696.

45. Taylor SJ, Manara AR, Brown J. Treating delayed gastric emptying in critical illness: metoclopramide, erythromycin, and bedside (cortrak) nasointestinal tube placement. JPEN J Parenter Enteral Nutr 2010; 34: 289–294.

46. Kim KH, Kim TH, Choi JY et al. Acupuncture for symptomatic relief of gastroparesis in a diabetic haemodialysis patient. Acupunct Med 2010; 28: 101–103.

47. Arai K, Takeuchi Y, Watanabe H et al. Prokinetics influence the pharmacokinetics of rabeprazole. Digestion 2008; 78: 67–71.

48. Lee TH, Choi JJ, Kim DH et al. Gastroprokinetic effects of DA-9701, a new prokinetic agent formulated with Pharbitis Semen and Corydalis Tuber. Phytomedicine 2008; 15: 836–843.

49. Takanashi H, Cynshi O. Motilides: a long and winding road: lessons from mitemcinal (GM-611) on diabetic gastroparesis. Regul Pept 2009; 155: 18–23.